Latest filing published 28 Oct 2020 for Perspective Therapeutics, Inc., €8,463.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +45.2%Entry US$4.20 · Close at T+365 US$6.10
- +26.2%Entry US$4.20 · Close at T+365 US$5.30
- -25.0%Entry US$5.60 · Close at T+365 US$4.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Alan Hoffmann: trading record in brief
Alan Hoffmann is a declared insider of Perspective Therapeutics, Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 8 December 2016 to 22 October 2020, the count stands at 3 filings.
The open-market record is one-sided, with 3 purchases worth €28k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2020: 1 purchase and no sales on the market.
In size, the median ticket on the buying side is €8,730. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 3 purchases show a median change of +0.0%, with the price up in 33% of them. Past outcomes like these are no guarantee of what comes next.
On 28 October 2020 came the latest disclosure, an open-market purchase for €8,463 in Perspective Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 6 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Alan Hoffmann
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 19,230 shares@ US$0.52100.0% of flowCommon StockSEC:0001437749-20-021851:0Canonical exit: 20 Jan 2021 (T+90)
- 25,000 shares@ US$0.4050.8% of flowCommon stockSEC:0001437749-18-021286:0Canonical exit: 18 Feb 2019 (T+90)
- 20,000 shares@ US$0.5738.1% of flowCommon stockSEC:0001642247-16-000011:0Canonical exit: 8 Mar 2017 (T+90)
3 of 3 declarations